B-cell lymphoma recurrent+1
RecruitingStudy of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab
Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab
- Disease:B-cell lymphoma recurrentB-cell lymphoma refractory
- Substances:CarboplatinDexamethasone+6
Austria- Participants:0–17 years · 18–64 years
- Substances:Carboplatin







